Crossmark

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

Crossref DOI link: https://doi.org/10.1007/s00277-024-06033-y

Published Online: 2024-10-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huls, Gerwin

Chitu, Dana A.

Tick, Lidwine

Boersma, Rinske

Breems, Dimitri

Herbers, Alexandra

Klein, Saskia K.

de Jonge, Suzan

Westerweel, Peter E.

Cruijsen, Marjan

Hoogendoorn, Mels

Cuijpers, Marlous

Deeren, Dries

Bailly, Benjamin

Visser, Otto

van Rhenen, Anna

Posthuma, Eduard F. M.

Valk, Peter J. M.

Cloos, Jacqueline

Ammatuna, Emanuele

Refos, Jeannine M.

Fakkert, R.

Löwenberg, Bob

Ossenkoppele, Gert J.
License Information

Text and Data Mining valid from 2024-10-05

Version of Record valid from 2024-10-05
More Information

Article History

Received: 23 July 2024

Accepted: 27 September 2024

First Online: 5 October 2024

Declarations

:

: This study was approved by the Medical Ethical committee of the University Medical Centre Groningen, and all participants provided informed consent in accordance with the Declaration of Helsinki. This investigator-sponsored trial was financially supported by Janssen Pharmaceutics who provided decitabine free of charge and Novartis who supported the trial and provided midostaurin free of charge.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below